丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06872 丹诺医药-B

已收盘 08-31 16:08:46

188.200

+0.000

0.00%

最高191.000	最低184.100	成交量4.32万
今开188.400	昨收188.200	日振幅3.67%
总市值98.48亿	流通市值98.48亿	总股本5,233万
成交额813.96万	换手率0.08%	流通股本5,233万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06872","market":"HK","secType":"STK","nameCN":"丹诺医药-B","latestPrice":188.2,"timestamp":1788163726822,"preClose":188.2,"halted":0,"volume":43150,"delay":0,"changeRate":0,"floatShares":52328926,"shares":52328926,"eps":-3.845134,"marketStatus":"已收盘","change":0,"latestTime":"08-31 16:08:46","open":188.4,"high":191,"low":184.1,"amount":8139625,"amplitude":0.036663,"askPrice":188.4,"askSize":1400,"bidPrice":186.6,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-3.065,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"listingDate":1779379200000,"exchange":"SEHK","adjPreClose":188.2,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.751873,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06872","defaultTab":"news","newsList":[{"id":"2662079166","title":"丹诺医药-B(06872.HK)发布中期业绩，股东应占亏损6424.5万元 同比收窄17.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662079166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662079166?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:15","pubTimestamp":1787735733,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189688927","title":"丹诺医药-B2026年上半年业绩：营收0元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189688927","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189688927?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:06","pubTimestamp":1787735219,"startTime":"0","endTime":"0","summary":"公司2026年上半年尚无商业化产品，营业收入为0元。研发开支为3,132.10万元，同比增长约19%，主要由于加快推进核心候选药物NDA审评及其他管线产品的临床进展所致。行政开支为3,201.30万元，同比增长约72%，部分原因在于上市开支及限制性股票成本增加。经营活动现金流出净额约为5,922.70万元，同比增长约48%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"丹诺医药-B2026年上半年业绩：营收0元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661135262","title":"丹诺医药-B(06872.HK)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2661135262","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661135262?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:45","pubTimestamp":1787309129,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06872","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660023238","title":"【生物医药小白投研】第一篇：打破认知盲区，建立底层框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2660023238","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660023238?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:30","pubTimestamp":1787214600,"startTime":"0","endTime":"0","summary":"生物医药是A股和港股中最特殊的赛道，没有之一。本篇旨在帮助读者打破固有思维，搭建生物医药投资的底层认知框架，为后续的选择、排雷、交易体系打好基础。康方生物：2025年商业化产品销售收入30.33亿元，同比增长51.48%。目前该公司已有4款产品获批上市。典型案例是2026年ASCO期间，康方生物和信达生物等发布了重磅临床数据，但当日股价表现平平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650513943&idx=1&sn=7cbba7ab46d98a94d953d8e9b60809e2&chksm=f30e7cf71bc535c0c64240524852e4b36187629cca446e9bd382f04ea70a74b68d1ffd38d5ce&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["IE00B5MMRT66.SGD","LU2097828631.EUR","KURE","IE00BZ08YR35.GBP","LU2097828805.USD","06990","LU0501845795.SGD","LU2242644610.SGD","LU1226287875.USD","02396","LU0561508036.HKD","09926","01093","LU1720050803.USD","LU2097828557.USD","LU0540923850.HKD","LU2488822045.USD","IE00BZ08YS42.EUR","BK1521","LU0348767384.USD","LU0348783233.USD","03692","LU0067412154.USD","01177","06872","LU1951186391.HKD","IE00BPRC5H50.USD","IE0008369823.USD","LU0140636845.USD","LU1152091168.USD","LU1328277881.USD","LU2097828714.EUR","LU0634319403.HKD","LU2039709279.SGD","LU0348735423.USD","09939","LU1226287792.SGD","01801","LU2778985437.USD","LU0463099449.HKD","IE0008368742.USD","LU2328871848.SGD","LU0326950275.SGD","BK1583","LU2097828474.EUR","SG9999004220.SGD","LU0880133367.SGD","LU0244354667.USD","LU1226287529.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195766769","title":"丹诺医药-B（06872）拟于8月26日审议2026年中期业绩及股息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1195766769","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195766769?lang=zh_cn&edition=full","pubTime":"2026-08-14 16:36","pubTimestamp":1786696593,"startTime":"0","endTime":"0","summary":"丹诺医药-B（06872）14日公告称，公司董事会将于2026年8月26日（星期三）召开会议，主要议程包括：一是审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布；二是考虑派发中期股息（如有）。\\n\\n公告显示，董事会目前由执行董事马振坤博士（兼董事会主席、首席执行官及总经理）、非执行董事宋高广博士，以及独立非执行董事李维刚先生、倪琳博士和李乐平博士组成。\\n\\n公司提醒投资者，相关中期业绩及分红方案的最终结果仍待董事会正式审议并通过后另行公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130610641","title":"丹诺医药-B 7月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1130610641","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130610641?lang=zh_cn&edition=full","pubTime":"2026-08-03 14:55","pubTimestamp":1785740137,"startTime":"0","endTime":"0","summary":"丹诺医药-B于2026年8月3日发布2026年7月股份变动月报表，报告期为2026年7月1日至7月31日。根据公告，截至报告期末，公司普通股H股已发行股份数为52,328,926股，与上个月末保持一致。公告显示，报告期内公司已发行及注册股本无新增或减少情况，普通股H股的已发行股份由上月底的52,328,926股保持不变，库藏股数量亦为0股。公司未发生任何股份购回、注销及新发行情况，也未披露股份期权或股权激励计划相关变动事宜。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193535160","title":"丹诺医药-B 2026年6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193535160","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193535160?lang=zh_cn&edition=full","pubTime":"2026-07-03 14:04","pubTimestamp":1783058666,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年7月3日发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司已发行普通股（H股）数量为52,328,926股，与5月底数量一致，报告期内无新增发行、购回、注销或股份回购后持作库藏的情况。公司确认，截至本月末，已满足香港联合交易所有限公司的公众持股量要求。报告期内，公司无可换股债券、股权激励及其他权益工具的变动事宜。截至6月底，公司股本结构整体保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01609","02272","00068","03625","01956","09630","03661","00600","01511","01021","01191","02616","00340","01672","03388","07688","03310","03355","01133","01286","02335","02726","06106","BK4585","06636","01392","01866","02142","07666","02632","06872","01440","06675","00100","01081","06658","00863","00412","02729","01779","02672","BK4588","09637","02670","00376","03277","02526","02696","06938","02553","03887","01236","02723","01879","06656","07630","01651"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641870064","title":"丹诺医药-B(06872)：宋高广获委任为薪酬与考核委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2641870064","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641870064?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:12","pubTimestamp":1780927959,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)发布公告，非执行董事宋高广博士已获委任为董事会薪酬与考核委员会成员，任期自2026年6月8日起生效，至第一届董事会任期届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641813110","title":"丹诺医药-B(06872)：Michael James Bakes辞任非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2641813110","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641813110?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:48","pubTimestamp":1780660131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)发布公告，由于个人工作原因调整，Michael James Bakes先生已辞任非执行董事并因此自动辞去董事会薪酬与考核委员会成员职务，自2026年6月5日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183051567","title":"丹诺医药-B发布2026年5月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1183051567","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183051567?lang=zh_cn&edition=full","pubTime":"2026-06-02 19:06","pubTimestamp":1780398379,"startTime":"0","endTime":"0","summary":"丹诺医药(苏州)股份有限公司于2026年6月2日公布了截至2026年5月31日的股份变动月报表。公告显示，公司H股股份于2026年5月22日在香港联合交易所有限公司主板新上市，报告期内股本结构保持稳定。公司同时确认，截至本月底，已符合适用的公众持股量要求。自报告期结束至今，公司未有新增发行及回购活动，股本维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143533014","title":"异动解读 | 核心产品前景广阔，丹诺医药-B盘中大涨5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143533014","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143533014?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:06","pubTimestamp":1779851217,"startTime":"0","endTime":"0","summary":"丹诺医药-B今日盘中大涨5.94%，引起了市场的广泛关注。消息面上，公司公开发售阶段获得9015.11倍的超额认购，成为今年港股主板超购倍数第二高的新股，显示出市场对其的强烈兴趣。更重要的是，公司的核心产品利福特尼唑是全球首个针对幽门螺杆菌感染的新分子实体候选药物，已于去年8月向国家药监局提交新药上市申请，预计今年底获批。中国幽门螺杆菌感染率约44%，涉及超6亿患者，市场空间极为广阔。此外，公司的另一核心产品利福喹酮注射剂正在推进全球III期临床试验，这是目前唯一处于后期临床开发阶段的人工关节感染小分子候选药物。这些积极进展共同增强了投资者对公司未来发展的信心，推动了股价的上涨。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637391400","title":"港股收评：恒指涨0.86% 科指涨2.11% 科网股普涨 人工智能板块强势 智谱涨超26% 丹诺医药上市首日涨超178%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637391400","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637391400?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:08","pubTimestamp":1779437280,"startTime":"0","endTime":"0","summary":"　　5月19日消息，港股三大指数集体上涨。截至收盘，恒生指数涨0.86%，报25606.03，恒生科技指数涨2.11%，国企指数涨0.89%。盘面上，科网股普涨，联想绩后涨超19%，网易涨超5%，百度、小米、快手涨超1%；半导体板块走强，兆易创新涨超12%；人工智能板块全天强势，智谱涨超26%；今日丹诺医药上市，首日涨超178%。公开发售阶段丹诺医药-B获9015.11倍认购，公开发售的发售股份最终数目为82.81万股股份，占发售股份总数的约9.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-05-22/doc-inhyufhk8455118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348816934.USD","03037","LU0254981946.USD","IE00B0169L03.USD","82800","81024","LU0228659784.USD","LU1770034418.SGD","IE00B97KM107.HKD","LU0049853897.USD","HSTECH","IE0031814852.USD","LU0348825331.USD","LU0831103253.SGD","LU1048596156.SGD","BK1587","LU1115378108.SGD","LU1188198961.HKD","LU1226288253.USD","LU1956131251.USD","02833","LU0856984785.SGD","LU0449515922.USD","LU1785774172.SGD","07300","LU0359201885.HKD","LU1951186391.HKD","LU2097828557.USD","LU2279701549.SGD","LU0164880469.USD","LU1226287875.USD","SG9999001051.SGD","LU2152927971.USD","LU0501845795.SGD","LU0543330566.HKD","LU0315179316.USD","LU1105468828.SGD","06872","03423","LU1481107354.HKD","HK0000306685.HKD","LU0084288322.USD","09888","LU0052750758.USD","LU0211977185.USD","LU0540923850.HKD","LU0828237510.HKD","LU2476274720.SGD","SG9999001846.SGD","BK1117","LU0287142896.SGD","BK1526","LU1046422090.SGD","03115","LU0307460666.USD","LU1366334651.USD","XIACY","LU1235295612.USD","LU0169518387.USD","83115","LU1880383440.USD","LU1770036033.HKD","IE00B0JY6N72.USD","BK1523","LU1226287529.USD","09088","09067","LU0345775950.USD","LU0708995583.HKD","LU0918141887.USD","LNVGY","LU1794554557.SGD","LU2257852520.SGD","SG9999002463.SGD","09999","LU0370786039.SGD","LU0823397103.USD","HK0000320223.HKD","LU0348805143.USD","LU1251922891.USD","LU0762540952.USD","LU0244354667.USD","02837","BK1502","LU0117841782.USD","SG9999014674.SGD","HK0000165453.HKD","LU1048588211.SGD","BK1588","LU2097828631.EUR","LU0455707207.USD","81810","IE00BZ08YS42.EUR","LU0561508036.HKD","LU0823038988.USD","LU1808992512.USD","LU0499858438.USD","BK1607","513600","LU0192582467.USD","LU0531971595.HKD","LU1282648689.USD","LU0890818403.SGD","LU0106959298.USD","LU2097828474.EUR","IE00B031J352.USD","LU0327786744.USD","LU0463099449.HKD","LU0821914370.USD","01810","LU0320764599.SGD","LU0797268264.HKD","LU0348767384.USD","80992","LU0359202008.SGD","LU1023057109.AUD","LU1267930227.SGD","LU1323998911.USD","LU0348827113.USD","LU0791590937.USD","LU2476274308.USD","LU0630378429.USD","HSI","03033","03032","LU0348814723.USD","09115","LU0164865239.USD","LU2399975544.HKD","HXXD.SI","LU0264606111.USD","BK1609","07500","LU0329678170.USD","LU2778985437.USD","03067","BK1591","LU0868486357.SGD","07552","IE0032834883.USD","LU0173614495.USD","LU1813983027.USD","LU0329678337.USD","LU0762542818.HKD","LU0823039010.USD","IE0008368742.USD","LU0456846285.SGD","MCHmain","IE0003795394.USD","BK1608","03419","IE00B031HY20.USD","LU0359201612.USD","LU0164872284.USD","LU0143863784.USD","LU0972618739.USD","LU1366334578.USD","LU0210526637.USD","LU0314109678.HKD","LU0502904849.HKD","LU1981816686.USD","LU0634319403.HKD","LU0737861699.HKD","LU2294711473.HKD","LU0823426308.USD","IE0003851619.USD","IE00B3M56506.USD","LU0229945570.USD","LU0823426480.USD","LU0348735423.USD","LU0106252389.USD","LU0128525689.USD","LU1303224171.USD","07200","NTES","LU1224709979.USD","BK1618","LU0918141705.HKD","LU1831875114.USD","IE00BZ08YR35.GBP","LU0588546209.SGD","HK0000320264.USD","LU0228367735.SGD","LU0640798160.USD","LU1734074674.USD","LU0143863198.USD","LU0163747925.USD","HHImain","BK1506","BIDU","IE0034224299.USD","LU0650527681.SGD","LU0823413587.USD","LU0611395673.USD","HK0000286598.CNH","LU0441854154.USD","LU1655091459.SGD","01024","LU1880383366.USD","LU0197773673.USD","LU1328615791.USD","LU0456827905.SGD","LU1868837565.USD","LU0188438112.USD","BK1615","LU0531970944.HKD","LU0630378692.HKD","LU0737861772.HKD","LU0823040885.USD","LU0700851271.USD","LU0594300179.USD","BK1610","03088","LU1807302812.USD","LU0572940350.SGD","LU2051468812.USD","89888","LU0823413660.USD","LU1226287792.SGD","SG9999002828.SGD","LU0049112450.USD","LU0683595622.HKD","LU0149721374.USD","07226","LU0675040207.SGD","LU0048580855.USD","LU0633140560.USD","LU2087589342.USD","BK1521","IE0032431581.USD","LU1961090484.USD","LU0572939691.SGD","LU0054450605.USD","BK1095","BK1531","LU0072913022.USD","LU0417516902.SGD","LU0348766576.USD","LU0140636845.USD","LU0594300419.USD","03417","BK1575","LU0633140727.USD","BK1589","LU0417516738.SGD","LU0072462343.USD","LU0051755006.USD","HK0000306701.USD","LU2097828805.USD","LU1328277881.USD","BK1104","BK1193","LU0231483743.USD","LU0823397285.USD","IE0008369823.USD","LU0572944931.SGD","LU1226288170.HKD","IE0009570106.USD","LU0310800965.SGD","LU0235996351.USD","LU2226246903.HKD","LU0039217434.USD","LU0345776255.USD","LU0819121731.USD","00992","LU0499858602.USD","BK1590","IE00B29SXG58.USD","LU2242644610.SGD","LU0043850808.USD","LU1688375341.USD","LU0052756011.USD","LU0449509016.USD","LU1720050803.USD","LU0791591158.USD","MIUmain","LU2097828714.EUR","02800","LU1719994722.HKD","LU0210527791.USD","LU0784639295.USD","LU0862451837.USD","IE00BZ08YT58.USD","SG9999001093.SGD","KSTmain","02513","LU0431992006.USD","LU0862451753.SGD","LU0326950275.SGD","IE00B067MR52.USD","LU0762541174.USD","LU0823041008.USD","LU0593848301.USD","LU0117844026.USD","LU0898667661.SGD","LU0197773160.USD","LU0214875030.USD","LU1226288097.SGD","LU0871576103.HKD","LU1675838814.USD","LU1868838027.USD","LU2039709279.SGD","LU0469268626.HKD","LU0831093199.SGD","SG9999003461.SGD","LU0605514214.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637531362","title":"丹诺医药-B(6872.HK)今日首日在港挂牌上市，股价上涨154%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637531362","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637531362?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:07","pubTimestamp":1779419227,"startTime":"0","endTime":"0","summary":"丹诺医药-B今日首日在港挂牌上市，盘初股价一度上涨154.29%，报192.5港元。据悉，该股在公开发售阶段获9,000倍超额认购，成为今年以来港股主板市场超购倍数第二高的新股。其新药上市申请已于2025年8月获国家药监局受理，预计于2026年底获得批准。另一核心产品利福喹酮注射剂，是全球首个在临床可实现剂量下有望对生物膜感染有效的新分子实体候选药物，亦是目前唯一处于临床开发用于治疗人工关节感染的小分子候选药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260522/32246220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06872","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637364922","title":"丹诺医药今起上市，手握两大全球首创抗菌新药获国际顶级医药基金AMR重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2637364922","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637364922?lang=zh_cn&edition=full","pubTime":"2026-05-22 10:30","pubTimestamp":1779417052,"startTime":"0","endTime":"0","summary":"丹诺医药首秀表现出彩。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637552369","title":"新股首日 | 丹诺医药-B涨幅扩大至130%，核心产品利福特尼唑有望年底获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2637552369","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637552369?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:44","pubTimestamp":1779414256,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丹诺医药-B首挂上市，公告显示，每股定价75.7港元，共发行885.6万股股份，每手50股，所得款项净额约5.58亿港元。目前，丹诺医药已建立由七项候选药物组成的管线，聚焦尚无或缺乏治疗手段的适应证领域。丹诺医药已于2025年8月向国家药监局提交新药上市申请，该药物有望于2026年底获批。目前，该产品已向国家药监局及美国FDA提交III期多领域临床试验方案。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444861.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192762179","title":"异动解读｜丹诺医药-B盘中上涨95.24%，上市首日获超9000倍认购火爆开局","url":"https://stock-news.laohu8.com/highlight/detail?id=1192762179","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192762179?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:36","pubTimestamp":1779413784,"startTime":"0","endTime":"0","summary":"5月22日，丹诺医药-B盘中上涨95.24%，报173.6港元，成交额2.11亿港元。消息面上，丹诺医药香港公开发售获9015.11倍认购，市场热度极高。全球幽门螺杆菌治疗市场规模预计至2035年攀升至161亿美元，中国感染率高达44%，涉及超6亿患者，市场空间广阔。丹诺医药于2013年成立，是一家临近商业化阶段的生物科技公司，专注于细菌感染及细菌代谢相关疾病领域创新药研发，已建立由七项创新项目组成的管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637369754","title":"港股新股丹诺医药涨近100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637369754","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637369754?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:30","pubTimestamp":1779413430,"startTime":"0","endTime":"0","summary":"5月22日，截至发稿，港股新股丹诺医药-B(06872.HK)涨98.15%。该公司在公开发售阶段获9015.11倍认购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605223746165377.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223746165377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","VXUS","06872","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133190677","title":"丹诺医药-B香港首秀开盘价剑指150港元，较发行价75.70港元近乎翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1133190677","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133190677?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:22","pubTimestamp":1779412940,"startTime":"0","endTime":"0","summary":"丹诺医药-B的股票在万众瞩目的香港交易所首次亮相中，即将迎来开门红。其开盘价预计将直接冲上每股150港元的高位，这一价格与每股75.70港元的发行定价相比，实现了惊人的翻倍增长，预示着市场对这家生物科技公司的高度热情与强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333621","title":"丹诺医药-B(06872)：香港公开发售获9015.11倍认购 全球发售净筹约5.98亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333621","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637333621?lang=zh_cn&edition=full","pubTime":"2026-05-21 19:48","pubTimestamp":1779364131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丹诺医药-B(06872)公布配发结果，公司全球发售885.6万股股份，香港公开发售占9.35%，国际发售占90.65%。每股发售价75.7港元，全球发售净筹约5.98亿港元。每手买卖单位50股H股，预期H股将于香港时间2026年5月22日(星期五)上午九时正于联交所开始买卖。其中，香港公开发售获9,015.11倍认购，国际发售获9.24倍认购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06872"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tennortherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.05},{"period":"1month","weight":0.1372},{"period":"3month","weight":-0.0756},{"period":"6month","weight":1.4861},{"period":"ytd","weight":1.4861}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.0086},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0234},{"period":"ytd","weight":-0.0018}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"丹诺医药（苏州）股份有限公司是一家主要从事发现、开发创新药产品的中国公司。该公司专注于细菌感染和代谢相关疾病领域。该公司的产品包括治疗幽门螺杆菌的新分子实体候选药物利福特尼唑(TNP-2198)、三靶点抗菌候选药物利福喹酮(TNP-2092)注射剂和治疗肠道菌群代谢相关疾病的多靶点抗菌候选药物TNP-2092口服制剂等。","exchange":"SEHK","name":"丹诺医药-B","nameEN":"TENNOR THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"丹诺医药-B,06872,丹诺医药-B股票,丹诺医药-B股票老虎,丹诺医药-B股票老虎国际,丹诺医药-B行情,丹诺医药-B股票行情,丹诺医药-B股价,丹诺医药-B股市,丹诺医药-B股票价格,丹诺医药-B股票交易,丹诺医药-B股票购买,丹诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"丹诺医药-B(06872)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供丹诺医药-B(06872)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}